Founded in 1998, Xvivo Perfusion AB specializes in ex vivo organ perfusion technologies that address the critical shortage of viable donor organs. The company operates through three primary business segments: Thoracic (lung and heart), Abdominal (liver and kidney), and Services (organ recovery and transport logistics). Its flagship products include the XVIVO Perfusion System (XPS), the Kidney Assist Transport device, and proprietary preservation fluids such as STEEN Solution and PERFADEX Plus. Xvivo employs a razor/razorblade business model, generating the majority of its revenue from the recurring sale of single-use disposables and consumables required for its capital equipment. With a presence in over 70 countries, the company holds a leading global market position in lung perfusion and is actively expanding its footprint in heart and abdominal organ preservation.
